The EIF2AK1 Knockout NCI-H1975 Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal population derived from the NCI-H1975 human lung adenocarcinoma cell line. This model disrupts the EIF2AK1 gene, encoding the heme-regulated inhibitor (HRI) kinase, enabling investigation of its role in the integrated stress response. The polyclonal format avoids clonal selection bias and preserves population-level heterogeneity for robust functional studies.
NCI-H1975 is a widely used non-small cell lung cancer (NSCLC) model established from a non-smoking female with lung adenocarcinoma. These epithelial cells harbor activating EGFR L858R and TP53 mutations, making them valuable for studying oncogenic signaling and stress adaptation. The cell line??s sensitivity to EGFR-targeted therapies offers a clinically relevant context for gene perturbation analyses.
EIF2AK1 (HRI) phosphorylates eIF2?? in response to heme deficiency, oxidative stress, heat shock, arsenite, or nitric oxide. This inhibits global translation while selectively promoting ATF4 synthesis, which then activates stress-responsive genes such as CHOP, GADD34, and PPP1R15A. HRI is allosterically inhibited by heme and stabilized by the chaperone Hsp90, integrating iron availability and proteotoxic stress to regulate downstream effectors that determine survival or apoptosis during cellular stress.
In the NCI-H1975 background, EIF2AK1 knockout likely impairs the ability to adapt to metabolic and oxidative challenges, potentially altering tumor cell survival under nutrient deprivation or chemotherapeutic stress. Since these cells rely on EGFR-driven signaling, loss of HRI may uncover dependencies between oncogenic pathways and the integrated stress response, providing insights into drug resistance mechanisms and synthetic lethal interactions in lung adenocarcinoma. This model enables dissection of how HRI-mediated stress adaptation intersects with mutant EGFR and TP53 signaling networks.
Researchers can employ this polyclonal knockout population in a variety of functional assays: quantitative western blotting for phospho-eIF2?? and ATF4; RT-qPCR analysis of CHOP, GADD34, and other stress markers; cell viability and apoptosis assays under heme depletion or oxidative stress; flow cytometry for stress-responsive proteins; metabolic profiling; and drug sensitivity screens. These applications facilitate detailed investigation of the integrated stress response, oxidative stress adaptation, and resistance mechanisms in NSCLC. For technical support or product inquiries, please contact Ascent Research.
